Amgen Inc. (AMGN): Analyst Consensus and Price Target
ByAinvest
Tuesday, Sep 16, 2025 3:04 pm ET1min read
AMGN--
The earnings report highlighted Amgen's strong performance across its various therapeutic areas. The company's revenue growth was driven by increased sales of its key products, including biosimilars and biologic therapies. The significant improvement in GAAP EPS underscores the company's operational efficiency and effective cost management.
Amgen's stock has shown resilience despite the broader market volatility. The company's strong earnings report has been well-received by investors, with analysts maintaining a bullish outlook. The median price target suggests that Amgen's stock has the potential to appreciate further, driven by its solid financial performance and the expectation of future growth.
In addition to its Q2 results, Amgen has been actively expanding its pipeline and exploring strategic partnerships to bolster its position in the biopharmaceutical industry. The company's focus on innovation and growth strategies is likely to continue supporting its financial performance in the coming quarters.
Overall, Amgen's Q2 2025 earnings report demonstrates the company's strong financial health and growth potential. The company's robust performance and analysts' positive outlook suggest that Amgen is well-positioned to continue delivering value to shareholders.
Amgen Inc. (AMGN) reported Q2 2025 earnings with total revenues increasing 9% to $9.2 billion and GAAP EPS rising 92% to $2.65. Analysts maintain a Moderate Buy consensus with a median price target of $276.39, implying a 12.16% upside from current levels.
Amgen Inc. (AMGN) reported its Q2 2025 earnings on September 12, 2025, with total revenues increasing 9% to $9.2 billion. The company's GAAP EPS rose by 92% to $2.65, reflecting robust financial performance. Analysts maintain a Moderate Buy consensus with a median price target of $276.39, indicating a 12.16% upside from current levels [1].The earnings report highlighted Amgen's strong performance across its various therapeutic areas. The company's revenue growth was driven by increased sales of its key products, including biosimilars and biologic therapies. The significant improvement in GAAP EPS underscores the company's operational efficiency and effective cost management.
Amgen's stock has shown resilience despite the broader market volatility. The company's strong earnings report has been well-received by investors, with analysts maintaining a bullish outlook. The median price target suggests that Amgen's stock has the potential to appreciate further, driven by its solid financial performance and the expectation of future growth.
In addition to its Q2 results, Amgen has been actively expanding its pipeline and exploring strategic partnerships to bolster its position in the biopharmaceutical industry. The company's focus on innovation and growth strategies is likely to continue supporting its financial performance in the coming quarters.
Overall, Amgen's Q2 2025 earnings report demonstrates the company's strong financial health and growth potential. The company's robust performance and analysts' positive outlook suggest that Amgen is well-positioned to continue delivering value to shareholders.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet